While further investigations into the specific roles and mechanisms of DNT cells in inflammatory or tumor environments are needed, there are currently four CAR-DNT studies registered on Clinicaltrials.gov, two of which focusing on safety and efficacy of CD19-CAR-DNT in the treatment of autoimmune diseases (Table 2). This evidence concerns the gene CD19 and neoplasm.